Literature DB >> 3762967

Cerebrospinal fluid C9 in demyelinating disease.

D A Compston, B P Morgan, D Oleesky, R Fifield, A K Campbell.   

Abstract

We measured CSF and plasma concentrations of C9, IgG, and albumin in 91 patients with demyelination and 73 controls with other neurologic diseases. The C9 index was reduced and IgG index increased in patients with multiple sclerosis and those with isolated demyelinating lesions, irrespective of disease activity; abnormalities were less marked in patients with isolated lesions than in those with MS. Humoral mechanisms may not be responsible for initiating demyelination, but activation of the complement system could amplify tissue damage and account for some symptomatic recovery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762967     DOI: 10.1212/wnl.36.11.1503

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.

Authors:  D A Compston; N M Milligan; P J Hughes; J Gibbs; V McBroom; B P Morgan; A K Campbell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

Review 2.  The complement system in central nervous system diseases.

Authors:  H Rus; F Niculescu
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers.

Authors:  Andrea Nova; Teresa Fazia; Ashley Beecham; Valeria Saddi; Marialuisa Piras; Jacob L McCauley; Carlo Berzuini; Luisa Bernardinelli
Journal:  Life (Basel)       Date:  2022-01-20

Review 4.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

5.  Reversible injury of cultured rat oligodendrocytes by complement.

Authors:  N J Scolding; W A Houston; B P Morgan; A K Campbell; D A Compston
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

6.  Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders.

Authors:  J Roddy; I Clark; B L Hazleman; D A Compston; N J Scolding
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

7.  Systemic complement profiling in multiple sclerosis as a biomarker of disease state.

Authors:  G Ingram; S Hakobyan; C L Hirst; C L Harris; S Loveless; J P Mitchell; T P Pickersgill; N P Robertson; B P Morgan
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

8.  Complement activation in multiple sclerosis plaques: an immunohistochemical analysis.

Authors:  Gillian Ingram; Sam Loveless; Owain W Howell; Svetlana Hakobyan; Bethan Dancey; Claire L Harris; Neil P Robertson; James W Neal; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2014-05-09       Impact factor: 7.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.